MS Views and News Be empowered with MS views and news. To receive The MS BEACON e-Newsletter, CLICK HERE - -

Visit our MS learning channel on YouTube, which provides hundreds of MS educational videos presented by MS Experts from across the USA. Archived here: www.youtube.com/msviewsandnews -- Also please visit our Social media platforms: Facebook, Twitter, and Instagram . Each providing important information for the MS community. Furthermore, scroll down the left side of this blog to learn from the resources and links.

Disclaimer: 'MS Views and News' DOES NOT endorse any products or services found on this blog. It is up to you to seek advice from your healthcare provider. The intent of this blog is to provide information on various medical conditions, medications, treatments, for your personal knowledge and to keep you informed of current health-related issues. It is not a substitute for the advice of your physician. Should you or your family members have any specific medical problem, seek medical care promptly.

~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~


Friday, October 21, 2011

Natalizumab (Tysabri)-Associated PML Survival Rates Exceed 80%


AMSTERDAM—Early diagnosis through enhanced clinical vigilance and optimal management of progressive multifocal leukoencephalopathy (PML) may improve outcomes, according to data presented at the ECTRIMS/ACTRIMS 5th Joint Triennial Congress. Survival rates in excess of 80% were seen in the first 133 postmarketing natalizumab-associated PML cases, reported Ludwig Kappos, MD, from the Departments of Neurology and Biomedicine, University Hospital, Basel, Switzerland, and colleagues. Improved survival was associated with younger age (median 43 versus 51.5) and less disability (median EDSS 4.0 versus 5.5) at diagnosis, shorter time from symptom onset to diagnosis (mean 40 versus 53 days), and more localized disease on brain MRI, as compared with fatal cases.

Of 159 PML cases identified in the post-marketing setting, 130 patients were still alive as of September 1, 2011 (82% survival rate). In survivors with more than six months of follow-up, 13% had mild disability, 47% had moderate disability, and 40 % had severe disability.



===========================================================
Remain CURRENT with Multiple Sclerosis news and information  
Providing You with MS Views and News, is what we do 
~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~ 
On the Fourth Wednesday of Each Month
Visit: StuMSradio - With Deanna and Stu
* Call (347) 215-9265 *
 To listen, speak with us or speak with a guest
~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~ 
"MS Views and News" is a 501©(3) Not-for-Profit organization as 
recognized by the Internal Revenue Service. 
All contributions are tax deductible to the fullest extent allowed by law.
~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
Disclaimer:  'MS Views and News' (MSVN), does not endorse any products or services found on this blog. It is up to you to seek advice from your healthcare provider. The intent of this blog is to provide information on various medical conditions, medications, treatments, and procedures for your personal knowledge and to keep you informed of current health-related issues. It is not intended to be complete or exhaustive, nor is it a substitute for the advice of your physician. Should you or your family members have any specific medical problem, seek medical care promptly. .

No comments: